RNA in cancer

GJ Goodall, VO Wickramasinghe - Nature Reviews Cancer, 2021 - nature.com
While the processing of mRNA is essential for gene expression, recent findings have
highlighted that RNA processing is systematically altered in cancer. Mutations in RNA …

Control of mammalian gene expression by selective mRNA export

VO Wickramasinghe, RA Laskey - Nature reviews Molecular cell biology, 2015 - nature.com
Nuclear export of mRNAs is a crucial step in the regulation of gene expression, linking
transcription in the nucleus to translation in the cytoplasm. Although important components …

In situ structural analysis of the human nuclear pore complex

A Von Appen, J Kosinski, L Sparks, A Ori, AL DiGuilio… - Nature, 2015 - nature.com
Nuclear pore complexes are fundamental components of all eukaryotic cells that mediate
nucleocytoplasmic exchange. Determining their 110-megadalton structure imposes a …

[HTML][HTML] Control of transcript variability in single mammalian cells

N Battich, T Stoeger, L Pelkmans - Cell, 2015 - cell.com
A central question in biology is whether variability between genetically identical cells
exposed to the same culture conditions is largely stochastic or deterministic. Using image …

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

NJ Bahlis, H Sutherland, D White… - Blood, The Journal …, 2018 - ashpublications.org
Selinexor is an oral inhibitor of the nuclear export protein exportin 1. Preclinical studies
demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors …

Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma

DT Vogl, D Dingli, RF Cornell, CA Huff… - Journal of clinical …, 2018 - ascopubs.org
Purpose Selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, induces
apoptosis in cancer cells through nuclear retention of tumor suppressor proteins and the …

Personalized immunotherapy against several neuronal and brain tumors

S Kuttruff-coqui, T Weinschenk, J Fritsche… - US Patent …, 2021 - Google Patents
2014-11-12 Assigned to IMMATICS BIOTECHNOLOGIES GMBH reassignment IMMATICS
BIOTECHNOLOGIES GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT …

Targeting tumour-supportive cellular machineries in anticancer drug development

M Dobbelstein, U Moll - Nature reviews Drug discovery, 2014 - nature.com
Traditional anticancer chemotherapeutics targeting DNA replication and cell division have
severe side effects, but they have proved to be highly successful in treating some cancers …

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia

R Garzon, M Savona, R Baz, M Andreeff… - Blood, The Journal …, 2017 - ashpublications.org
Selinexor is a novel, first-in-class, selective inhibitor of nuclear export compound, which
blocks exportin 1 (XPO1) function, leads to nuclear accumulation of tumor suppressor …

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma

J Kuruvilla, M Savona, R Baz… - Blood, The Journal …, 2017 - ashpublications.org
Patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) have a poor
prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first …